SCHEMBL4442829

SCHEMBL4442829

CC(=O)Nc1cccc2c(S(=O)(=O)NCc3ccco3)cccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
LMNA P02545 4/20 0.57
MAPK1 P28482 3/20 0.57
NPSR1 Q6W5P4 1/20 0.57
POLB P06746 7/20 0.55
MAPT P10636 2/20 0.55
ALOX15 P16050 2/20 0.55
TSHR P16473 2/20 0.55
HPGD P15428 1/20 0.55
ALOX12 P18054 1/20 0.55
HSD17B10 Q99714 4/20 0.50
CASP1 P29466 3/20 0.50
CASP7 P55210 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 2/20 0.50
EDNRA P25101 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.49
KMT2A Q03164 2/20 0.48
TP53 P04637 1/20 0.48
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449108 0.83 EDNRA (0.52) ALDH1A1LMNAMAPK1NPSR1MAPT
SCHEMBL29900505 0.80 EDNRA (0.55) ALDH1A1MAPK1TSHRHPGDKDM4E
SCHEMBL23092875 0.80 EDNRA (0.55) ALDH1A1MAPK1TSHRHPGDKDM4E
SCHEMBL4443344 0.79 LMNA (0.55) LMNATSHRSMN1; SMN2EDNRA
SCHEMBL4450789 0.79 EDNRA (0.49) EDNRAKMT2A
SCHEMBL4446573 0.78 NSD2 (0.63) ALDH1A1LMNAMAPK1NPSR1POLB
SCHEMBL4446944 0.78 NSD2 (0.64) ALDH1A1LMNAHPGDKDM4EEDNRA
SCHEMBL4448161 0.78 NPY5R (0.50) POLBEDNRAKMT2AMEN1
SCHEMBL4448416 0.78 NSD2 (0.54) EDNRA
SCHEMBL4449304 0.78 CCR8 (0.53) ALDH1A1POLBHPGDKDM4EEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547716-B2 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-06-16 US disclosed
US-7531334-B2 Polymeric microcarriers for cell culture functions XEROX CORPORATION (US) 2009-05-12 US disclosed
EP-1402890-B1 SULFONAMIDE DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2008-01-09 EP disclosed
US-20070243607-A1 POLYMERIC MICROCARRIERS FOR CELL CULTURE FUNCTIONS XEROX CORPORATION (US) 2007-10-18 US disclosed
US-7276254-B2 Emulsion/aggregation polymeric microspheres for biomedical applications and methods of making same XEROX CORPORATION (US) 2007-10-02 US disclosed
US-20040234622-A1 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-11-25 US disclosed
EP-1402890-A1 SULFONAMIDE DERIVATIVES Institute of Medicinal Molecular Design, Inc. (JP) 2004-03-31 EP disclosed
US-20030211035-A1 Emulsion/aggregation polymeric microspheres for biomedical applications and methods of making same XEROX CORPORATION 2003-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040234622-A1 Sulfonamide derivatives PCNA, TOP2A, DDB1 ALDH1A1 980/4885LMNA 1312/4885MAPK1 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.